Aviva
OYST

Aviva’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Aviva’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-34,238
Closed -$989K – 957
2020
Q2 		$989K Buy
+34,238
New +$1.03M 0.01% 873

Other funds holding OYST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Aviva's OYST Position: Q3 2020 in Review

Aviva sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q3 2020, closing a stake of 34,238 shares — an estimated $989K sold.

Aviva first reported a position in OYST in Q2 2020 and held it in 1 quarter. The position peaked at $989K in Q2 2020. 66 funds tracked by Wall St. Rank hold OYST as of Q3 2020.

  • Aviva reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Aviva sold 34,238 Oyster Point Pharma, Inc. Common Stock shares in Q3 2020, an estimated $989K.
  • Aviva first reported a position in Oyster Point Pharma, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Aviva's Oyster Point Pharma, Inc. Common Stock position peaked at $989K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q3 2020.

Based on Aviva's 13F filing for Q3 2020, filed 12 Nov 2020.